share_log
Moomoo 24/7 ·  Feb 29 08:12
VYNE Therapeutics Ended 2023 With $93.3M Of Cash, Cash Equivalents, Restricted Cash And Marketable Securities, Providing Runway Through The End Of 2025
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment